Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results – Medical Marijuana Program Connection

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the third quarter of 2023 ended September 30, 2023. “The third quarter of 2023 was a period of significant progress for our team as we completed sever

Source link